Alfredo Castro - Ikena Oncology Ex Discovery
| IKNA Stock | USD 1.71 0.02 1.16% |
Insider
Alfredo Castro is Ex Discovery of Ikena Oncology
| Address | 645 Summer Street, Boston, MA, United States, 02210 |
| Phone | 857 273 8343 |
| Web | https://ikenaoncology.com |
Ikena Oncology Management Efficiency
The company has return on total asset (ROA) of (0.2206) % which means that it has lost $0.2206 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3709) %, meaning that it created substantial loss on money invested by shareholders. Ikena Oncology's management efficiency ratios could be used to measure how well Ikena Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.37. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Ikena Oncology's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.7 M, whereas Other Current Assets are forecasted to decline to about 2.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Eliem Therapeutics | 63 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Hing Wong | HCW Biologics | 70 | |
| BBA CPA | Lumos Pharma | 57 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Lisa Miller | Lumos Pharma | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Lori CPA | Lumos Pharma | 40 | |
| James JD | Eliem Therapeutics | 58 | |
| Carl Langren | Lumos Pharma | 69 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Susan MS | Eliem Therapeutics | N/A | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| David MBA | Seres Therapeutics | 63 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Bradley JD | Lumos Pharma | 45 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.22 |
Ikena Oncology Leadership Team
Elected by the shareholders, the Ikena Oncology's board of directors comprises two types of representatives: Ikena Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ikena. The board's role is to monitor Ikena Oncology's management team and ensure that shareholders' interests are well served. Ikena Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ikena Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Schroeder, Sr Operations | ||
| Rebecca Cohen, Corporate Relations | ||
| Valdas Jurkauskas, Senior Operations | ||
| MBA MD, Chief Officer | ||
| David MS, Senior Operations | ||
| Navin MS, VP Quality | ||
| Sabine Ruppel, VP Discovery | ||
| Srividya Esq, VP Counsel | ||
| Jotin MD, CFO Development | ||
| Alfredo Castro, Ex Discovery | ||
| Michelle Zhang, Chief Officer | ||
| Samantha Vuksanic, Head Resources | ||
| Mark Manfredi, CEO President | ||
| Bob Lally, Senior Operations | ||
| Evan Hecker, VP CMC | ||
| Jeffrey Ecsedy, Chief Officer | ||
| Alexander Constan, Senior DMPK | ||
| Caroline MD, Chief Officer |
Ikena Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ikena Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (97.55) % | ||||
| Current Valuation | (47.12 M) | ||||
| Shares Outstanding | 48.26 M | ||||
| Shares Owned By Insiders | 10.49 % | ||||
| Shares Owned By Institutions | 63.58 % | ||||
| Number Of Shares Shorted | 129.88 K | ||||
| Price To Earning | 3.89 X | ||||
| Price To Book | 0.61 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ikena Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ikena Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ikena Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ikena Oncology Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Revenue Per Share 0.014 | Quarterly Revenue Growth (0.88) | Return On Assets (0.22) | Return On Equity (0.37) |
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.